Literature DB >> 8872331

Cathepsins D, B, and L in transformed human breast epithelial cells.

T T Lah1, G Calaf, E Kalman, B G Shinde, R Somers, S Estrada, E Salero, J Russo, I Daskal.   

Abstract

To investigate the regulation of lysosomal enzymes during carcinogenesis, we measured cathepsins (Cats) D, B, and L in MCF-10F, which is a human breast epithelial cell line, and cells evolved after treatment with carcinogen and transfected with c-Ha-ras oncogene. The clones used in this study, MCF-10FTras, D3, D3-1, and D3-1Tras, expressed no estrogen receptors and gradually increased invasive potential, while oncogene-transfected lines were also tumorigenic in SCID mice [16, 19]. Cats D, B, and L were determined in the cells and in cell media using enzyme-linked immunosorbent assay (ELISA), specific enzyme activity measurements, and immunocytochemistry. The major intra- and extracellular lysosomal proteinase in these cells was Cat D (30-180 pm/mg), followed by Cat B (2-10 pm/mg) and Cat L (1-5 pm/mg). An inverse relationship between intracellular Cat D levels and invasive potential of carcinogen-treated and c-Ha-ras oncogene-transfected cell lines was observed. No significant changes in extracellular concentration of Cat D precursor in this series of cell lines was observed. Intracellular levels of Cats B and L were unchanged or slightly lower in carcinogen-treated D3 and D3-1 cells, as well as in MCF-10FTras. On the other hand, in D3-1Tras cell line, evolving from c-Ha-ras transfected D3-1 line, 3.5 fold and 4.4 fold increases in Cat B and Cat L, respectively, but a 2 fold decrease in Cat D, were observed compared to the parental cell line. Immunocytochemical staining showed a granular, polarized perinuclear and cytoplasmic staining of cathepsins in all cell lines. Cysteine proteinases stained more frequently and more intensely in D3-1Tras compared to other lines, confirming the immunochemical assays. We hypothesize that several molecular events, caused by a carcinogen and an oncogene such as c-Ha-ras, are needed to increase Cat B and Cat L, but not Cat D, expression. Therefore, the cysteine and aspartic lysosomal proteinases are differentially expressed in the breast cell lines with more invasive phenotype.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872331     DOI: 10.1007/bf01806189

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  33 in total

Review 1.  The role of cathepsin L in malignant transformation.

Authors:  S E Kane; M M Gottesman
Journal:  Semin Cancer Biol       Date:  1990-04       Impact factor: 15.707

2.  Protein turnover in 3T3 cells transformed with the oncogene c-H-ras1.

Authors:  J M Gunn; G James
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

3.  Stefins and lysosomal cathepsins B, L and D in human breast carcinoma.

Authors:  T T Lah; M Kokalj-Kunovar; B Strukelj; J Pungercar; D Barlic-Maganja; M Drobnic-Kosorok; L Kastelic; J Babnik; R Golouh; V Turk
Journal:  Int J Cancer       Date:  1992-01-02       Impact factor: 7.396

4.  The identification of active forms of cysteine proteinases in Kirsten-virus-transformed mouse fibroblasts by use of a specific radiolabelled inhibitor.

Authors:  R W Mason; D Wilcox; P Wikstrom; E N Shaw
Journal:  Biochem J       Date:  1989-01-01       Impact factor: 3.857

5.  Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras-transformed NIH 3T3 cells.

Authors:  A F Chambers; R Colella; D T Denhardt; S M Wilson
Journal:  Mol Carcinog       Date:  1992       Impact factor: 4.784

6.  Identification and characterization of cells deficient in the mannose 6-phosphate receptor: evidence for an alternate pathway for lysosomal enzyme targeting.

Authors:  C A Gabel; D E Goldberg; S Kornfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

7.  Regulation of protein degradation in normal and transformed human bronchial epithelial cells in culture.

Authors:  H K Lee; R T Jones; R A Myers; L Marzella
Journal:  Arch Biochem Biophys       Date:  1992-07       Impact factor: 4.013

8.  Hormone receptors and cathepsin D levels in human breast epithelial cells transformed by chemical carcinogens and c-Ha-ras transfection.

Authors:  G Calaf; Q Tahin; M E Alvarado; S Estrada; T Cox; J Russo
Journal:  Breast Cancer Res Treat       Date:  1994-02       Impact factor: 4.872

9.  Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene.

Authors:  B F Sloane; K Moin; M Sameni; L R Tait; J Rozhin; G Ziegler
Journal:  J Cell Sci       Date:  1994-02       Impact factor: 5.285

10.  Cytochemical and biochemical evidence of cathepsin B in malignant, transformed and normal breast epithelial cells.

Authors:  E Krepela; J Bártek; D Skalková; J Vicar; D Rasnick; J Taylor-Papadimitriou; R C Hallowes
Journal:  J Cell Sci       Date:  1987-02       Impact factor: 5.285

View more
  5 in total

Review 1.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

2.  The Expression of Lysosomal Proteinases and Their Inhibitors in Breast Cancer: Possible Relationship to Prognosis of the Disease.

Authors:  Tamara T Lah; Janko Kos; Andrej Blejec; Snezana Frkovic-Georgio; Rastko Golouh
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

Review 3.  Lysosomal enzymes, cathepsins in brain tumour invasion.

Authors:  Natasa Levicar; Tadej Strojnik; Janko Kos; Ricardo A Dewey; Geoffrey J Pilkington; Tamara T Lah
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

Review 4.  Xenograft models of premalignant breast disease.

Authors:  F R Miller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

Review 5.  Role of somatic cells on dairy processes and products: a review.

Authors:  N Li; R Richoux; M Boutinaud; P Martin; V Gagnaire
Journal:  Dairy Sci Technol       Date:  2014-07-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.